Febrile neutropenic events in cancer patients: treatment for fever and neutropenia in young adult patients during intensive chemotherapy for solid tumours.
Febrile neutropenic events (FNE) were studied in 90 patients on chemotherapy protocols for solid tumours, from 1986 to 1990. All patients received intensive chemotherapy with a high dose intensity. There were 51 FNE admissions in 31 patients, with an average event rate of 1.6/patient. The average periods of granulocytopenia, fever and admission were 3.5, 2.7 and 5.4 days respectively. The management of FNE consisted of accurate clinical observation and antibiotic treatment if indicated by symptoms of infection or by bacteriological cultures. Only 25 of 51 patients admitted received empiric broad-spectrum antibiotics, while 7 were treated after the results of bacteriological cultures were known. One patient died during granulocytopenia, of interstitial pneumonitis for which no bacteriological source was established. Recurrences of infection after discharge from the hospital were not seen. We conclude that in this group of young adult patients, FNE runs a favourable course. Only a short period of admission and a limited form of antibiotic treatment are needed, minimizing the load on the patient and the costs of their care.
Nobbenhuis
M
M
Department of Clinical Oncology, Leiden University Hospital, The Netherlands.
Cleton
F J
FJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001419:Bacteria / Q000302:isolation & purification; D005334:Fever / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000188:drug therapy*; D012189:Retrospective Studies
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents